Get the Stockscreener App
172.99
0.76%
1.31
After Hours:
174.20
1.21
+0.70%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $172.99, with a volume of 8.47M.
It is up +0.76% in the last 24 hours and down -19.34% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$171.68
Open:
$172.57
24h Volume:
8.47M
Relative Volume:
1.22
Market Cap:
$316.82B
Revenue:
$56.33B
Net Income/Loss:
$4.28B
P/E Ratio:
72.08
EPS:
2.4
Net Cash Flow:
$17.83B
1W Performance:
-0.69%
1M Performance:
-19.34%
6M Performance:
-8.26%
1Y Performance:
+5.32%
1-Day Range:
$171.91
$175.20
1-Week Range:
$169.33
$180.50
52-Week Range:
$153.58
$218.66
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
172.99 | 316.82B | 56.33B | 4.28B | 17.83B | 2.40 |
|
LLY
Lilly Eli Co
|
839.96 | 677.40B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
157.47 | 371.98B | 89.33B | 21.81B | 18.06B | 8.99 |
|
NVO
Novo Nordisk Adr
|
58.08 | 293.24B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.86 | 216.19B | 51.72B | 11.94B | 13.81B | 5.88 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TradingView
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights – ABBV - TradingView
Is AbbVie Inc. (ABBV) the Best Large-Cap Value Stock to Buy as the Recession Hits? - Insider Monkey
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - marketscreener.com
Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market - GlobeNewswire Inc.
AbbVie (ABBV): A Top Dividend Monarch with Strong Growth Prospects - GuruFocus
Applications now open for Abbvie’s cystic fibrosis scholarship program - Cystic Fibrosis News Today
AbbVie (ABBV) Gets a Buy from Guggenheim - The Globe and Mail
Fund Update: Bank Pictet & Cie (Europe) AG added 78,930 shares of ABBVIE ($ABBV) to their portfolio - Nasdaq
AbbVie Inc. (ABBV): Among the Innovative Healthcare Stocks to Watch in 2025 - Yahoo Finance
ABBV LAWSUIT ALERT: The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - marketscreener.com
AbbVie Inc. (ABBV) Stock Forecasts - Yahoo Finance
10 Innovative Healthcare Stocks to Watch in 2025 - Insider Monkey
AbbVie Inc. (ABBV): One of the Best Dividend Monarchs to Invest in Now - Insider Monkey
Interleukin Inhibitors Market Is Booming Worldwide | AbbVie - openPR.com
Drug company files suit against South Dakota over new 340B law - South Dakota Public Broadcasting
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks - Yahoo Finance
The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment - Nasdaq
Top Research Reports for AbbVie, TJX & Charles Schwab - MSN
AbbVie Asks Court to Extend Venclexta Cancer-Drug Patent’s Life - Bloomberg Law News
AbbVie Options Trading: A Deep Dive into Market Sentiment - Nasdaq
AbbVie Inc. (ABBV): One of the High Growth Forever Dividend Stocks to Invest In - Yahoo Finance
Drugmaker sues SD over law preserving broad access to discounts for hospitals, pharmacies - Argus Leader
The Zacks Analyst Blog Merck and AbbVie - Yahoo Finance
10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
AbbVie and Sandoz agree to drop court spat over Rinvoq patents - Endpoints News
ABBV vs. MRK: Which Drug Giant is a Better Buy Now? - Yahoo Finance
Arthralgia Market to Reach New Heights in Growth by 2032, - openPR.com
The Zacks Analyst Blog Merck And AbbVie - Barchart.com
Meta, TJX, Taiwan Semiconductor Manufacturing And A Health Care Stock: CNBC's 'Final Trades' - Benzinga
Earnings Preview: What to Expect From AbbVie's Report - Nasdaq
Earnings Preview: What To Expect From AbbVie's Report - Barchart.com
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis - Yahoo Finance
10 High Growth Forever Dividend Stocks To Invest In - Insider Monkey
Is AbbVie Inc. (ABBV) the Best Stock for 15 Years? - Yahoo Finance
Skin Boosters Market to Witness Stunning Growth with AbbVie, Medytox, ExoCoBio - openPR.com
AbbVie (ABBV) Faces Volatility Despite Positive Earnings in Q1 2 - GuruFocus
AbbVie, Sandoz Settle Patent Fight Over Rinvoq Generics - Law360
Multiple Myeloma Pipeline 2025: Latest FDA Approvals, Clinical - openPR.com
AbbVie Unusual Options Activity - Benzinga
AbbVie (NYSE:ABBV) Shares Down 5.6%Should You Sell? - MarketBeat
AbbVie Aesthetics Line Faces Potential Risk in Current Macro Environment, UBS Says - MarketScreener
AbbVie Brings New Suits Against State Pharmacy Contract Laws - Bloomberg Law News
Pharma Stock Roundup: EU Nod to Expanded Use of ABBV, AZN Drugs & More - TradingView
Ex-Dividend Reminder: Buckle, AbbVie and Abbott Laboratories - Nasdaq
Here’s Why Clearbridge Growth Strategy Sold AbbVie (ABBV) - Insider Monkey
ABBV Stock Upgraded to Buy Amid Valuation Insights - GuruFocus
AbbVie Files Lawsuits to Block Drug Pricing Laws in North Dakota and South Dakota - USA Herald
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
7.63%
2.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):